No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ETNB250117P35000
- 0.00
- 0.000.00%
15min DelayTrading Dec 23 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest35.00Strike Price0.00Turnover0.00%IV-338.32%PremiumJan 17, 2025Expiry Date27.02Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.30Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
89bio Strengthens Leadership Retention With New RSUs
Express News | 89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
89Bio Inc. Reports Q3 2024 Financial Results
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024